Ripretinib intrapatient dose escalation after disease progression provides clinically meaningful outcomes in advanced gastrointestinal stromal tumour
- Suzanne George
- , Ping Chi
- , Michael C. Heinrich
- , Margaret von Mehren
- , Robin L. Jones
- , Kristen Ganjoo
- , Jonathan Trent
- , Hans Gelderblom
- , Albiruni A. Razak
- , Michael S. Gordon
- , Neeta Somaiah
- , Julia Jennings
- , Julie Meade
- , Kelvin Shi
- , Ying Su
- , Rodrigo Ruiz-Soto
- , Filip Janku
- Dana-Farber Cancer Institute
- Cornell University
- Oregon Health and Science University
- Royal Marsden Hospital
- Stanford University
- University of Miami
- Leiden University
- Princess Margaret Cancer Centre
- HonorHealth, Arizona
- University of Texas MD Anderson Cancer Center
- Deciphera Pharmaceuticals, LLC.
Research output: Contribution to journal › Article › peer-review
25
Scopus
citations